FDA staffers tee up Gilead's hep C drug sofosbuvir for upbeat panel meeting

Gilead Sciences ($GILD) may be able to break out the champagne soon if the FDA's review of its hepatitis C drug sofosbuvir is any indication. Ahead of Friday's advisory panel meeting, the agency's staff highlighted sofosbuvir's all-oral treatment approach, with faster cures and fewer side effects than older meds. Report